Logo

Medco

Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
Premium

Roche made a splash last year with its repeated overtures to acquire genome sequencing firm Illumina, but for the most part, 2012 was a quiet year during which players in the life sciences industry took modest steps to increase their capabilities to advance personalized treatment

People in the News: Robert Epstein, Erin O'Shea
Premium

Illumina announced that Robert Epstein has joined its board of directors. Epstein formerly was chief R&D officer and president of Medco-UBC, and he was Medco’s chief medical officer for 13 years.

People in the News: Felix Frueh, Stephen Quake, Jack Davis
Premium

Third Rock Ventures has hired Felix Frueh as an entrepreneur-in-residence.

Buying Remaining Stake in Generation Health, CVS Caremark Keeps PGx Programs but Cuts Staff
Premium

Originally published Aug. 23.

New Firm MetaDiagnostic Moves in to Help Dx Developers, Payors as PBMs Shift from Personalized Rx
Premium

Originally published Aug. 27.
May 9, 2012

Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
Premium

Mar 28, 2012

Knowledge of KIF6 Mutation Status Increases Patients' Statin Adherence, Medco Study Finds
Premium

Mar 14, 2012

Does Lack of PGx Link in Recent Studies Foreshadow End of CYP2D6 Genotyping for Tamoxifen?
Premium

Feb 29, 2012

Cepmed, DNA Direct Launch Personalized Rx Portal for Canada; Plan Real-World Implementation Studies
Premium

Feb 22, 2012

Demonstrating Cost Effectiveness of Clinical NGS is Key to Payor Reimbursement, Hospital Uptake
Premium

Jan 18, 2012

AssureRx Updates PGx Test for Assessing Best Responders to Psychotropic Drugs
Premium

Dec 14, 2011

FDA Looks into Pradaxa Bleeding Risk; What Does it Mean for PGx-Guided Warfarin Dosing?
Premium

Nov 21, 2011

Archon Genomics X Prize Begins Recruiting Players, Centenarians

Nov 2, 2011

As More Patients Gain Knowledge of Genetic Makeup, FDA Warns Against Biased Personalized Rx Trials
Premium

Nov 2, 2011

Pfizer's Deal with Medco's UBC Could Shed Light on New Personalized Rx Opportunities
Premium

Oct 26, 2011

Archon X Prize Signs on Medco as Sponsor; Competitors to Sequence 100 Centenarians
Premium

Oct 26, 2011

Pfizer, Medco Team on 'Precision Medicine' Effort

Oct 26, 2011

X Prize, Medco Team on $10M Centenarian Sequencing Prize

Oct 19, 2011

Medco Study Suggests Genetic Testing Improves Patient Compliance with Statins
Premium

Aug 15, 2011

Prometheus Labs, Medco Research Partner on Companion Dx for IBD

Jul 27, 2011

Fate of Medco's Personalized Medicine Programs Uncertain Under Express Scripts' Acquisition Plan
Premium

Jun 29, 2011

Sanofi's CER Deal with Medco's UBC Could Help ID Potential PGx Drugs in Pipeline
Premium

Jun 23, 2011

Medco, Sanofi Partner on PGx, Comparative Effectiveness

Jun 8, 2011

Medco Taps MolecularMD to Provide BCR-ABL Testing for TKI Inhibitors in CML Patients
Premium

Jun 2, 2011

Medco Offering MolecularMD Companion Dx Test for Tyrosine Kinase Inhibitor Response

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.